European Medicines Agency Has Reset The Review Of Apellis Pharmaceuticals' Intravitreal Pegcetacoplan For Geographic Atrophy To The Last Phase Of The Initial Assessment (Day 180). Apellis Anticipates An Opinion From CHMP No Later Than July 2024
歐洲藥品管理局已將對Apellis Pharmicals的玻璃體內Pegcetacoplan地理萎縮的審查重置爲初步評估的最後階段(第180天)。Apellis 預計 CHMP 不遲於 2024 年 7 月發表意見